EPS8L3 promotes pancreatic cancer proliferation and metastasis by activating GSK3B

EPS8L3 promotes pancreatic cancer

  • Zun Fan
  • Ming Li
  • Yinjie Xu
  • Chenxing Ge
  • Jianfeng Gu Department of General Surgery, Changshu No.1 People’s Hospital Affiliated to Soochow University
DOI: https://doi.org/10.5937/jomb0-38840
Keywords: EPS8L3, GSK3B, pancreatic cancer, proliferation, metastasis

Abstract


Background: We intended to investigate the role and regulatory mechanism of EPS8L3 in increase the development of pancreatic cancer (PC).

Methods: In order to analyze the relationship between EPS8L3 level and clinicopathological indicators of PC patients, qRT-PCR was used to detect the expression of EPS8L3 in tumor specimens of 40 PC patients. EPS8L3 knockdown models were then constructed in PC cell lines. Furthermore, the effect of EPS8L3 on PC cell function was analyzed by CCK-8 and Transwell assay. Dual luciferase reporter gene assay and recovery assay were used to further investigate the underlying mechanism.

Results: qRT-PCR results indicated that EPS8L3 was highly expressed in PC tissues compared with adjacent ones. At the same time, the incidence of distant metastasis was higher in PC patients with high EPS8L3 level. In vitro analysis such as CCK-8 and Transwell experimentations indicated that knockdown of EPS8L3 markedly inhibited the proliferative and metastatic ability. Bio-informatics together with luciferase report assay proposing that EPS8L3 can target GSK3B. Western Blot results revealed that knockdown of EPS8L3 markedly reduced the GSK3B expression in PC cells, and there was a positively associated between the two in PC cells. In addition, the recovery experimentation proved that EPS8L3 and GSK3B have a mutual regulation effect. Overexpression of GSK3B can reversal the prohibitive effect of EPS8L3 knockdown on the malignant development of PC cells, thereby jointly regulating the occurrence and development of PC.

Conclusions: EPS8L3 promotes the development of PC by regulating GSK3B, suggesting that EPS8L3 can be used as a biomarker for early diagnosis and treatment of PC.

References

1. Jackaman C, Tomay F, Duong L, Abdol RN, Pixley FJ, Metharom P, et al. Aging and cancer: The role of macrophages and neutrophils. Ageing Res Rev 2017; 36: 105-16.
2. Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular Senescence: Aging, Cancer, and Injury. Physiol Rev 2019; 99(2): 1047-78.
3. Bernardes DJB, Blasco MA. Telomerase at the intersection of cancer and aging. Trends Genet 2013; 29(9): 513-20.
4. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9694-705.
5. Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol 2016; 12(16): 1929-46.
6. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018; 24(43): 4846-61.
7. Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer 2018; 17(1): 108.
8. Yang J, Ren B, Yang G, Wang H, Chen G, You L, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci 2020; 77(2): 305-21.
9. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16(4): 207-20.
10. Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology 2019; 156(7): 2024-40.
11. Di Fiore PP, Scita G. Eps8 in the midst of GTPases. Int J Biochem Cell Biol 2002; 34(10): 1178-83.
12. Li YH, Xue TY, He YZ, Du JW. Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol 2013; 9(10): 1587-94.
13. Cheng CY, Mruk DD. Regulation of spermiogenesis, spermiation and blood-testis barrier dynamics: novel insights from studies on Eps8 and Arp3. Biochem J 2011; 435(3): 553-62.
14. Yang G, Lu YB, Guan QL. EPS8 is a Potential Oncogene in Glioblastoma. Onco Targets Ther 2019; 12: 10523-34.
15. Zhang H, Zhou L, Zhou W, Xie X, Wu M, Chen Y, et al. EPS8-mediated regulation of multiple myeloma cell growth and survival. Am J Cancer Res 2019; 9(8): 1622-34.
16. Zeng CX, Tang LY, Xie CY, Li FX, Zhao JY, Jiang N, et al. Overexpression of EPS8L3 promotes cell proliferation by inhibiting the transactivity of FOXO1 in HCC. Neoplasma 2018; 65(5): 701-7.
17. Li P, Hu T, Wang H, Tang Y, Ma Y, Wang X, et al. Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer. Mol Med Rep 2019; 20(3): 2493-9.
18. Vujasinovic M, Valente R, Del CM, Permert J, Lohr JM. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients 2017; 9(3):
19. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015; 15(1): 8-18.
20. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015; 148: 114-31.
21. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11(8): 539-51.
22. Edderkaoui M, Chheda C, Soufi B, Zayou F, Hu RW, Ramanujan VK, et al. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Gastroenterology 2018; 155(6): 1985-98.
23. Ogunleye AJ, Olanrewaju AJ, Arowosegbe M, Omotuyi OI. Molecular docking based screening analysis of GSK3B. Bioinformation 2019; 15(3): 201-8.
Published
2022/08/06
Issue
Vol. 42 No. 1 (2023): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2022 Zun Fan, Ming Li, Yinjie Xu, Chenxing Ge, Jianfeng Gu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.